Shanghai Yizhong Pharmaceutical Co., Ltd.
public_traded
Shanghai Yizhong Pharmaceutical Co., Ltd. is publicly traded on SHH under ticker 688091.SS.
Shanghai Yizhong Pharmaceutical Co., Ltd. engages in the development of anti-tumor drugs and related products in China. It develops a dosage form of paclitaxel, an anti-tumor chemotherapeutic. The company was founded in 2009 and is based in Shanghai, China.